Vasculogenic Cell Therapy
Critical Limb Ischemia (CLI)
Key Facts
About Vascugen
Vascugen, founded in 2018, is a private, pre-clinical stage biotech advancing a novel iPSC-derived vasculogenic cell therapy platform. The company's technology aims to directly restore blood flow via vasculogenesis, differentiating it from failed angiogenic approaches. With a focus on high-unmet-need ischemic diseases and a potential application in tissue engineering, Vascugen is translating foundational research from its scientific founder into therapeutic candidates.
View full company profileAbout Vascugen
Vascugen, founded in 2018, is a private, pre-clinical stage biotech advancing a novel iPSC-derived vasculogenic cell therapy platform. The company's technology aims to directly restore blood flow via vasculogenesis, differentiating it from failed angiogenic approaches. With a focus on high-unmet-need ischemic diseases and a potential application in tissue engineering, Vascugen is translating foundational research from its scientific founder into therapeutic candidates.
View full company profile